Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer

NEXT STORY
Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer
PREV STORY
Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer

author_avatar
NASDAQ Market News

NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission

author_avatar
NASDAQ Market News

2017 Clinical Trial Strategies & Trends in Biosimilar Drug Development: A higher proportion of bioisimilar development projects is targeted towards regulated markets

Dublin, Jan. 12, 2018 (GLOBE NEWSWIRE) -- The "Clinical Trial Strategies in Biosimilar Drug ...

author_avatar
NASDAQ Market News